Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cytomx Thera (CTMX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 622,038
  • Shares Outstanding, K 45,010
  • Annual Sales, $ 71,620 K
  • Annual Income, $ -43,100 K
  • 36-Month Beta 1.46
  • Price/Sales 9.43
  • Price/Cash Flow N/A
  • Price/Book 4.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.53
  • Number of Estimates 7
  • High Estimate -0.40
  • Low Estimate -0.60
  • Prior Year 0.02
  • Growth Rate Est. (year over year) -2,750.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.75 +11.84%
on 11/06/18
17.26 -17.38%
on 10/17/18
-1.53 (-9.69%)
since 10/12/18
3-Month
12.75 +11.84%
on 11/06/18
24.34 -41.41%
on 08/29/18
-9.68 (-40.43%)
since 08/13/18
52-Week
12.75 +11.84%
on 11/06/18
35.00 -59.26%
on 03/08/18
-5.67 (-28.45%)
since 11/13/17

Most Recent Stories

More News
Cytomx Therapeut Shares Down 33.0% Since SmarTrend's Sell Call (CTMX)

SmarTrend identified a Downtrend for Cytomx Therapeut (NASDAQ:CTMX) on August 15th, 2018 at $22.40. In approximately 3 months, Cytomx Therapeut has returned 33.02% as of today's recent price of $15.00....

CTMX : 14.26 (+3.18%)
CytomX Therapeutics Presents CX-072 Clinical Translational Data at 2018 SITC Annual Meeting

- Demonstrates Further Proof-of-Mechanism of Probody(TM) Platform -

CTMX : 14.26 (+3.18%)
Clinical Study Advancements for New Cancer Drug Candidates Boosting Optimism in Oncology Therapy Industry

Financialnewsmedia.com News Commentary

CTMX : 14.26 (+3.18%)
HZNP : 21.85 (+0.51%)
LLY : 112.39 (-0.72%)
ABBV : 88.22 (-1.64%)
MBRX : 1.35 (+3.05%)
CytomX to Present at the Jefferies 2018 London Healthcare Conference

CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody(TM) therapeutic...

CTMX : 14.26 (+3.18%)
CytomX Therapeutics (CTMX) Reports Q3 Loss, Lags Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -26.19% and -23.81%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?...

CTMX : 14.26 (+3.18%)
CytomX Therapeutics Announces Third Quarter 2018 Financial Results

ESMO Presentations Support CX-072 Product Profile and Probody(TM) Proof-of-Concept

CTMX : 14.26 (+3.18%)
Shares of CTMX Down 32.6% Since Downtrend Call on Shares

SmarTrend identified a Downtrend for Cytomx Therapeut (NASDAQ:CTMX) on August 15th, 2018 at $22.40. In approximately 3 months, Cytomx Therapeut has returned 32.62% as of today's recent price of $15.09....

CTMX : 14.26 (+3.18%)
CytomX Therapeutics to Announce Third Quarter 2018 Financial Results

CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 14.26 (+3.18%)
Cytomx Therapeut Down 27.5% Since SmarTrend Downtrend Call (CTMX)

SmarTrend identified a Downtrend for Cytomx Therapeut (NASDAQ:CTMX) on August 15th, 2018 at $22.40. In approximately 2 months, Cytomx Therapeut has returned 27.48% as of today's recent price of $16.24....

CTMX : 14.26 (+3.18%)
30.3% Return Seen to Date on SmarTrend Cytomx Therapeut Call (CTMX)

SmarTrend identified a Downtrend for Cytomx Therapeut (NASDAQ:CTMX) on August 15th, 2018 at $22.40. In approximately 2 months, Cytomx Therapeut has returned 30.30% as of today's recent price of $15.61....

CTMX : 14.26 (+3.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade CTMX with:

Business Summary

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered...

See More

Key Turning Points

2nd Resistance Point 15.28
1st Resistance Point 14.77
Last Price 14.26
1st Support Level 13.66
2nd Support Level 13.06

See More

52-Week High 35.00
Fibonacci 61.8% 26.50
Fibonacci 50% 23.88
Fibonacci 38.2% 21.25
Last Price 14.26
52-Week Low 12.75

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar